| abstract |
Refers to compounds of formula I, where: Xa, Xb and Xc are independently CH or N; X1 is -(CHR12)s-NR1-Xe-C1-C4-alkanediyl-(SO2)p3- or -(CH2)s-O-Xe-C1-C4-alkanediyl-(SO2)p3-; Xe is -C(=O)-, among others; a is NR4-C(=O)-[C(R5b)2]r, NR4-C(R5b)2-C(=O)- or C(=O)-NR4-C(R5b)2; b is i), where Xd1 is CH or N, Xd2 is CH2 or NH; ring A is phenyl or pyridyl; R1 is hydrogen, C1-C4 alkyl, among others; R12 is hydrogen or C1-C4 alkyl; or R1 and R12 come together to form C1-C4 alkanediyl, among others; s is 0, 1 or 2; p3 is is 0 or 1; R3 is hydrogen, oxo, among others; R4 is hydrogen, C1-C4 alkyl or C1-C4 alkyloxy-C1-C4 alkyl; R5b is hydrogen, C1-C4 alkyl, among others; p2 and r are 0, 1 or 2; R6 is hydrogen, halo, among others; n is 1 or 2. Said compounds are inhibitors of EF2K and optionally have inhibitory activity of Vps34, being useful in the treatment of hematological malignancies and solid tumors such as glioblastoma, medulloblastoma, among others. |